aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.99−0.25 (-4.77%)
Close on Nov 17, 2026Market cap $489.46MP/E –Yield –
aTYR PHARMA profit margin
Profit margin (net margin) is net income as a percentage of revenue.
aTYR PHARMA's profit margin for the twelve months ending Dec 31, 2025 was -39009.5%. For fiscal 2025 it was -39009.5%, against -27243.8% the year before. The highest annual figure on record is -155.2% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -39009.5% | −11765.6 |
| FY2024 | Dec 31, 2024 | -27243.8% | −12969.3 |
| FY2023 | Dec 31, 2023 | -14274.5% | −13838.0 |
| FY2022 | Dec 31, 2022 | -436.5% | −281.4 |
| FY2020 | Dec 31, 2020 | -155.2% | +3689.4 |
| FY2019 | Dec 31, 2019 | -3844.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -13549.5% | −13309.2 |
| Q1 FY2024 | Mar 31, 2024 | -6591.9% | −2133.1 |
| Q3 FY2023 | Sep 30, 2023 | -3212.5% | +198.1 |
| Q4 FY2022 | Dec 31, 2022 | -72.4% | −94.2 |
| Q4 FY2020 | Dec 31, 2020 | -240.2% | +3907.7 |
| Q3 FY2020 | Sep 30, 2020 | -4458.8% | −1390.8 |
| Q2 FY2020 | Jun 30, 2020 | -3410.6% | +2810.7 |
| Q1 FY2020 | Mar 31, 2020 | 21.7% | – |
| Q4 FY2019 | Dec 31, 2019 | -4147.9% | – |
| Q3 FY2019 | Sep 30, 2019 | -3067.9% | – |
| Q2 FY2019 | Jun 30, 2019 | -6221.3% | – |
See a number that looks wrong?